| 摘要 |
In the present invention, during a clinical trial for a new drug, if an adverse event arises in a double blind test that includes the use of a control drug, a storage unit is referred to (S18) that stores a plurality of clinical trial patient groups containing a plurality of clinical trial patients to whom the new drug or the control drug has been administered or will be administered, a notification destination corresponding to the clinical trial patient group containing the clinical trial patients to whom the new drug has been administered or will be administered among the plurality of clinical trial patient groups that have been stored is notified (S22) of the occurrence of the adverse event, and the notification destination corresponding to the clinical trial patient groups not containing clinical trial patients to whom the new drug has been administered or will be administered is not notified (S24) of the occurrence of an adverse event, and so suitable notifications pertaining to clinical trials are carried out. |
